Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
SAR439459 is a monoclonal antibody that targets transforming growth factor beta 1 (TGFB1, TGFbeta), which may lead to tumor regression in combination with PD-1 (PDCD1) immune checkpoint inhibitors (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2790).
|DrugClasses||TGFB (Pan) Antibody 5|
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Atezolizumab + Bevacizumab + SAR439459||Atezolizumab Bevacizumab SAR439459||0||0|
|Cemiplimab + SAR439459||Cemiplimab SAR439459||0||2|
|Dexamethasone + Isatuximab + SAR439459||Dexamethasone Isatuximab SAR439459||0||1|